Humana (NYSE:HUM – Get Free Report) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Humana to post earnings of ($4.01) per share and revenue of $32.0804 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating the consensus estimate of $2.95 by $0.29. Humana had a net margin of 1.02% and a return on equity of 12.86%. The company had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. During the same period in the prior year, the firm posted $4.16 EPS. The firm’s revenue was up 11.1% compared to the same quarter last year. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $13 EPS for the next fiscal year.
Humana Stock Performance
Humana stock opened at $192.95 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.02 and a quick ratio of 2.02. The firm has a market capitalization of $23.21 billion, a P/E ratio of 18.08, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. Humana has a 1-year low of $186.00 and a 1-year high of $315.35. The company’s 50-day moving average is $254.70 and its 200 day moving average is $263.84.
Hedge Funds Weigh In On Humana
Analyst Ratings Changes
A number of equities research analysts recently issued reports on HUM shares. Zacks Research lowered Humana from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 1st. Morgan Stanley reiterated an “underperform” rating on shares of Humana in a research note on Thursday, December 18th. Truist Financial lowered their target price on shares of Humana from $300.00 to $285.00 and set a “hold” rating for the company in a research note on Monday, November 10th. KeyCorp reaffirmed a “sector weight” rating on shares of Humana in a research note on Friday, December 12th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $344.00 price objective on shares of Humana in a report on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $293.21.
Check Out Our Latest Research Report on HUM
Humana Company Profile
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
See Also
- Five stocks we like better than Humana
- Your Bank Account Is No Longer Safe
- Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It
- 1 Hour Once A Day
- [No Brainer Gold Play]: “Show me a better investment.”
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
